Our previous SPORE had separate Cores for tissue collection/curation (old Core A: National Tissue Resource) and for pathologic evaluation (old Core C: Pathology), but in this new application they are combined in one Core, the National Tissue Resource and Pathology Core (NTRPC), since they are highly integrated and work closely with one another. The NTRPC also collaborates closely with Core B (Biostatistics and Data Management), which is responsible for informatics to manage inventory and annotation data. The objectives of the NTPRC are: (1) To provide centralized support for acquisition, banking, management, and distribution of tissue within the SPORE, and to maintain and update the databases with annotation and follow-up associated with these tissues. We will manage and distribute tissue and data from legacy inventories to qualified researchers, inside and outside our SPORE;collect, quality control, manage, and distribute newly acquired breast cancer materials including clinical trial specimens to qualified researchers;and annotate materials already in the collections from appropriately consented subjects with additional clinical, pathologic and follow-up information. (2) To provide histologic assessment and quality control of these tissues, along with tissue-based studies such as IHC using these clinical specimens as well as mouse tissues from the preclinical experiments. We will quality control and perform accurate pathologic assessment of tumors;and coordinate and manage the pathology support for the SPORE projects, developing new assays as required and working with the investigators to determine the methodologies most appropriate for their needs. The NTRPC is a continuation of two existing, well-functioning, and absolutely essential Cores. Although the guidelines state that

Public Health Relevance

Lack access to high quality, well annotated clinical specimens is a major impediment to progress in translational research. Core A has a long-standing and exemplary track record for making such tissues available to investigators inside and outside the SPORE. Further, breast cancer is a heterogeneous disease that requires trained histotechnologists, and very experienced pathologists to perform and interpret assays, and to properly handle valuable pre-clinical and highly annotated clinical specimens.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA186784-01
Application #
8747146
Study Section
Special Emphasis Panel (ZCA1-RPRB-C (M1))
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
$481,594
Indirect Cost
$192,627
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Mohammed, Somala; Sukumaran, Sujita; Bajgain, Pradip et al. (2017) Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther 25:249-258
Fu, Xiaoyong; Jeselsohn, Rinath; Pereira, Resel et al. (2016) FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proc Natl Acad Sci U S A 113:E6600-E6609
Dong, J; Zhao, W; Shi, A et al. (2016) The PR status of the originating cell of ER/PR-negative mouse mammary tumors. Oncogene 35:4149-54
Dobrolecki, Lacey E; Airhart, Susie D; Alferez, Denis G et al. (2016) Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev 35:547-573
Malorni, Luca; Giuliano, Mario; Migliaccio, Ilenia et al. (2016) Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res 14:470-81
Eedunuri, Vijay Kumar; Rajapakshe, Kimal; Fiskus, Warren et al. (2015) miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Mol Endocrinol 29:1170-83
Shi, Aiping; Dong, Jie; Hilsenbeck, Susan et al. (2015) The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia. PLoS One 10:e0132214
Sine, Jessica; Urban, Cordula; Thayer, Derek et al. (2015) Photo activation of HPPH encapsulated in ""Pocket"" liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts. Int J Nanomedicine 10:125-45
Dowst, Heidi; Pew, Benjamin; Watkins, Chris et al. (2015) Acquire: an open-source comprehensive cancer biobanking system. Bioinformatics 31:1655-62

Showing the most recent 10 out of 16 publications